- Home
- CIM vs ELVN Comparison
CIM vs ELVN Comparison
Compare CIM & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIM
- ELVN
- Stock Information
- Founded
- CIM 2007
- ELVN 2016
- Country
- CIM United States
- ELVN United States
- Employees
- CIM N/A
- ELVN N/A
- Industry
- CIM Real Estate Investment Trusts
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- CIM Real Estate
- ELVN Health Care
- Exchange
- CIM Nasdaq
- ELVN Nasdaq
- Market Cap
- CIM 1.1B
- ELVN 1.2B
- IPO Year
- CIM 2007
- ELVN 2020
- Fundamental
- Price
- CIM $14.14
- ELVN $20.85
- Analyst Decision
- CIM Buy
- ELVN Strong Buy
- Analyst Count
- CIM 3
- ELVN 5
- Target Price
- CIM $15.50
- ELVN $41.20
- AVG Volume (30 Days)
- CIM 509.5K
- ELVN 358.6K
- Earning Date
- CIM 08-06-2025
- ELVN 08-13-2025
- Dividend Yield
- CIM 10.47%
- ELVN N/A
- EPS Growth
- CIM N/A
- ELVN N/A
- EPS
- CIM 1.28
- ELVN N/A
- Revenue
- CIM $312,281,000.00
- ELVN N/A
- Revenue This Year
- CIM $18.51
- ELVN N/A
- Revenue Next Year
- CIM $3.88
- ELVN N/A
- P/E Ratio
- CIM $11.01
- ELVN N/A
- Revenue Growth
- CIM 1.91
- ELVN N/A
- 52 Week Low
- CIM $9.85
- ELVN $13.30
- 52 Week High
- CIM $16.89
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- CIM 58.86
- ELVN 56.87
- Support Level
- CIM $13.53
- ELVN $19.30
- Resistance Level
- CIM $13.93
- ELVN $21.01
- Average True Range (ATR)
- CIM 0.28
- ELVN 1.27
- MACD
- CIM 0.05
- ELVN 0.21
- Stochastic Oscillator
- CIM 96.45
- ELVN 86.37
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.